76,972 results match your criteria Acute Myelogenous Leukemia


Retroperitoneal Hematoma after Bone Marrow Biopsy: The First Cut Should Not Be the Deepest.

Oncol Res Treat 2019 Apr 17;42(5):279-284. Epub 2019 Apr 17.

Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany,

Bone marrow biopsies are standard hematology procedures. We report the case of a patient with acute myeloid leukemia who developed retroperitoneal hematoma after the procedure. The bleeding was stopped with endovascular embolization and coiling. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499743
Publisher Site
http://dx.doi.org/10.1159/000499743DOI Listing
April 2019
1 Read

Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.

N Engl J Med 2019 Apr;380(16):1525-1534

From the Departments of Bone Marrow Transplantation and Cellular Therapy (E.M., B.T., W.J., S.G.), Hematology (S.Z., Z.M., J.C., J.D., X.T., B.Y.R., M.J.W., B.P.S.), Therapeutics Production and Quality (T.L., M.M.M.), Immunology (H.A., B.Y.), Pharmaceutical Sciences (S.J.C.), Biostatistics (G.K., C.L.), and Infectious Diseases (G.M.), St. Jude Children's Research Hospital, Memphis, TN; the Allergy and Clinical Immunology Division, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru (J.C.A.B.); the Department of Pediatrics, Allergy-Immunology Division, Children's Hospital Los Angeles, Los Angeles (J.A.C.), and the Department of Pediatrics, Division of Pediatric Allergy-Immunology-Bone Marrow Transplantation, University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco (J.R.L.-B., J.M.P., M.J.C.) - both in California; the Department of Pediatrics, Pediatric Allergy and Immunology, University of New Mexico, Albuquerque (E.D.); University of Oklahoma Health Sciences Center, Tulsa (J.T.L.); Departamento de Pediatria da Universidade de Taubaté, Conselho Nacional de Medicina, São Paulo (A.C.M.A.); Copperfield Childcare, Claremont, South Africa (H.W.); and the Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (S.S.D.R., H.L.M.).

Background: Allogeneic hematopoietic stem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to reconstitute immunity associated with T cells, B cells, and natural killer (NK) cells when matched sibling donors are unavailable unless high-dose chemotherapy is given. In previous studies, autologous gene therapy with γ-retroviral vectors failed to reconstitute B-cell and NK-cell immunity and was complicated by vector-related leukemia.

Methods: We performed a dual-center, phase 1-2 safety and efficacy study of a lentiviral vector to transfer complementary DNA to bone marrow stem cells after low-exposure, targeted busulfan conditioning in eight infants with newly diagnosed SCID-X1. Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1815408
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1815408DOI Listing
April 2019
4 Reads

Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.

JCO Clin Cancer Inform 2019 Apr(3):1-10

1 All authors: Moffitt Cancer Center and Research Institute, Tampa, FL.

Purpose: Many cancers can be treated with targeted therapy. Almost inevitably, tumors develop resistance to targeted therapy, either from pre-existence or by evolving new genotypes and traits. Intratumor heterogeneity serves as a reservoir for resistance, which often occurs as a result of the selection of minor cellular subclones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.18.00074DOI Listing

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Genes Chromosomes Cancer 2019 Apr 17. Epub 2019 Apr 17.

MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377 Munich, Germany.

Deletions in the long arm of chromosome 7 (del(7q)) are recurrent cytogenetic aberrations in myeloid neoplasms. They occur either isolated or as part of a complex karyotype and are associated with unfavorable prognosis in certain disease entities. We performed detailed cytogenetic analysis, molecular analysis and array comparative genomic hybridization (aCGH) in a cohort of 81 patients with a variety of myeloid malignancies and del(7q) as sole chromosomal alteration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22761DOI Listing

Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.

Cancer Med 2019 Apr 16. Epub 2019 Apr 16.

Université Paris-Saclay, Université Paris-Sud, CESP (Center for Research in Epidemiology and Population Health), Inserm, Team Cancer and Environment, Villejuif, France.

We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high-risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI) <80% on the overall survival (OS). There were 51.6% of patients who had full dose and 48. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2121DOI Listing

The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.

Ann Hematol 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai, China.

To investigate the effect of chronic graft-versus-host disease (cGVHD) on the outcomes of acute myeloid leukemia (AML) patients who relapsed after allogenic hematopoietic cell transplantation, we performed a retrospective analysis on 218 patients with a median follow-up of 21.4 (3.4-179. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03682-2DOI Listing

Relapse Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Apparently Due to Somatic Cell Evolution via Epigenetic Variation and Immune Selection.

Authors:
Neil S Greenspan

Pathog Immun 2019 27;4(1):79-84. Epub 2019 Feb 27.

Case Western Reserve University, Cleveland, Ohio.

In this brief commentary, I discuss a recently published study that documents the role of immune escape in relapse of acute myeloid leukemia (AML) after hematopoietic cell transplantation (HCT). Of particular interest, the mechanism identified by the authors for the ability of the malignant cells to evade destruction by host T cells is the loss of cell surface expression of HLA class II molecules based on processes other than mutation. The authors labeled this mechanism for altered cell surface display of HLA class II antigens "epigenetic. Read More

View Article

Download full-text PDF

Source
https://paijournal.com/index.php/paijournal/article/view/285
Publisher Site
http://dx.doi.org/10.20411/pai.v4i1.285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423549PMC
February 2019
1 Read

The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.

Cancer Cell Int 2019 4;19:83. Epub 2019 Apr 4.

1Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.

Background: In addition to morphological and cytogenetic features, acute myeloid leukemias are characterized by mutations that can be used for target-therapy; also the minimal/measurable residual disease (MRD) could be an important prognostic factor. The purpose of this retrospective study was to investigate if somatic mutations could represent an additional prognostic value in respect of MRD alone.

Method: At baseline, 98 patients were tested for , , and for expression; 31 for , , , , -, , -, , and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0807-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449954PMC

CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.

Nat Chem Biol 2019 May 15;15(5):529-539. Epub 2019 Apr 15.

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.

Understanding the mechanism of small molecules is a critical challenge in chemical biology and drug discovery. Medicinal chemistry is essential for elucidating drug mechanism, enabling variation of small molecule structure to gain structure-activity relationships (SARs). However, the development of complementary approaches that systematically vary target protein structure could provide equally informative SARs for investigating drug mechanism and protein function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41589-019-0263-0DOI Listing

A Phase 1/2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed/ Refractory Acute Myeloid Leukemia.

Clin Cancer Res 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute.

Purpose: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains poor and novel therapies are needed. The proteasome pathway represents a potential therapeutic target. A phase 1 trial of the second generation proteasome inhibitor, ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3886DOI Listing

Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.

BMC Cancer 2019 Apr 16;19(1):358. Epub 2019 Apr 16.

Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Background: Micafungin is a well-tolerated and effective prophylactic antifungal agent used in hematologic diseases. In this prospective trial, we evaluated the efficacy and safety of prophylactic micafungin during first induction chemotherapy in patients with acute leukemia. We also compared outcomes of prophylactic micafungin with those of prophylactic posaconazole in acute myeloid leukemia (AML). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5557-9DOI Listing
April 2019
1 Read

Anthracycline-based consolidation may determine outcome of post-consolidation immunotherapy in AML.

Leuk Lymphoma 2019 Apr 17:1-8. Epub 2019 Apr 17.

a TIMM Laboratory , Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.

Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the impact of ICD in AML is only partly explored. We assessed aspects of ICD, as reflected by calreticulin expression, in primary human AML blasts and observed induction of surface calreticulin upon exposure to daunorubicin but not to cytarabine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1599110DOI Listing

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Cancer Cell 2019 Apr;35(4):677-691.e10

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of the Chinese Academy of Sciences, Beijing 100049, China. Electronic address:

FTO, an mRNA N-methyladenosine (mA) demethylase, was reported to promote leukemogenesis. Using structure-based rational design, we have developed two promising FTO inhibitors, namely FB23 and FB23-2, which directly bind to FTO and selectively inhibit FTO's mA demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108193015
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2019.03.006DOI Listing
April 2019
10 Reads

γ-Catenin-Dependent Signals Maintain BCR-ABL1 B Cell Acute Lymphoblastic Leukemia.

Cancer Cell 2019 Apr;35(4):649-663.e10

Department of Oncology UNIL CHUV, University of Lausanne, Epalinges, Switzerland. Electronic address:

The BCR-ABL1 fusion protein is the cause of chronic myeloid leukemia (CML) and of a significant fraction of adult-onset B cell acute lymphoblastic leukemia (B-ALL) cases. Using mouse models and patient-derived samples, we identified an essential role for γ-catenin in the initiation and maintenance of BCR-ABL1 B-ALL but not CML. The selectivity was explained by a partial γ-catenin dependence of MYC expression together with the susceptibility of B-ALL, but not CML, to reduced MYC levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.03.005DOI Listing

The Yin and Yang of RNA Methylation: An Imbalance of Erasers Enhances Sensitivity to FTO Demethylase Small-Molecule Targeting in Leukemia Stem Cells.

Cancer Cell 2019 Apr;35(4):540-541

Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address:

A prevalent eukaryotic N-methyladensosine (mA) post-transcriptional mark can be "erased" by the mA demethylase FTO, which is commonly deregulated in acute myeloid leukemia (AML). In this issue of Cancer Cell, Huang et al. design small-molecule FTO inhibitors, FB23 and FB23-2, and demonstrate their potent inhibitory impact in AML models. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108193015
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2019.03.011DOI Listing
April 2019
1 Read

microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1.

Cell Cycle 2019 Apr 16. Epub 2019 Apr 16.

d Department of Emergency Surgery , Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022 , China .

The microRNA miRNA-1225-5p (miR-1225) is known as an essential modulator of the development of multiple cancers and other biological reactions. However, the understanding of its contribution in pancreatic cancer (PC) is insufficient. The effects of miR-1225 on PC cell survival and tumorigenesis in vivo as well as on the modulation of cell apoptosis were investigated. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/15384101.2019.1
Publisher Site
http://dx.doi.org/10.1080/15384101.2019.1608127DOI Listing
April 2019
1 Read

Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia.

Am J Clin Pathol 2019 Apr 16. Epub 2019 Apr 16.

Division of Hematology and HSCT, Department of Oncology, King Abdul Aziz Medical City, Riyadh, KSA.

Objectives: The prevalence of concomitant myeloid neoplasms was recently reported to be unexpectedly high among adults without non-Langerhans cell histiocytosis (non-LCH); however, the coexistence of non-LCH with RUNX1 genetic aberration has not been reported previously.

Methods: Herein, we report a 23-year-old woman with severe pancytopenia diagnosed with non-LCH following presentation with pancytopenia and marrow examination showing histiocytosis positive for CD45, CD68, CD136, and lysozyme but negative for CD1a, langerin, and S100.

Results: Whole-exome sequencing showed RUNX1 mutation and NF1 mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz018DOI Listing

Di--lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity.

Int J Nanomedicine 2019 26;14:2091-2102. Epub 2019 Mar 26.

Micro & Nanomédecines Translationelles - MINT, UNIV Angers, INSERM 1066, CNRS 6021, University of Angers, MINT IBS-CHU, Larrey, 49933 Angers, France,

Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%-80% of cases. However, the prognosis is still poor for older patients, who are unfit for intensive chemotherapy, and only a few therapies are available. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/di-o-lauroyl-decitabine-lipid-nano
Publisher Site
http://dx.doi.org/10.2147/IJN.S190482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440450PMC
March 2019
1 Read

Marked Thrombocytosis and Megakaryocytic Dysplasia in NPM1 Mutated De-Novo Acute Myeloid Leukemia.

Indian J Hematol Blood Transfus 2019 Apr 19;35(2):380-381. Epub 2018 Nov 19.

Department of Hematology, All India Institute of Medical Sciences, New Delhi, 110029 India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1047-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439059PMC

Acute Myelopathy as the First Manifestation in a Hitherto Undiagnosed Case of Chronic Myeloid Leukemia.

Indian J Hematol Blood Transfus 2019 Apr 28;35(2):373-375. Epub 2019 Jan 28.

2Department of Internal Medicine, PGIMER, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-019-01081-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439020PMC

Outcome of Acute Myeloid Leukemia in Children Adolescents and Young Adults Treated with an Uniform Protocol in Casablanca, Morocco.

Indian J Hematol Blood Transfus 2019 Apr 25;35(2):255-259. Epub 2018 Sep 25.

1Department of Hematology and Pediatric Oncology, Hospital 20 August, University Hassan II Casablanca, Casablanca, Morocco.

Treatment of acute myeloblastic leukemia in children, adolescents and young adults (AYA) is a challenge in low-income countries. To evaluate treatment outcomes of children (≤ 15 years) and AYA (15-30 years) diagnosed with novo AML and treated in a single center according to the AML-MA 2011 protocol. From January 2011 to December 2015, eligible patients (age ≤ 30 years) with novo AML had been enrolled on a uniform treatment protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1013-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439122PMC

Outcomes of Intensive Treatment of Adult Acute Myeloid Leukemia Patients: A Retrospective Study From a Single Centre.

Indian J Hematol Blood Transfus 2019 Apr 1;35(2):248-254. Epub 2018 Oct 1.

Department of Medical Oncology, Cancer Institute (WIA), 36, Sardar Patel Road, Guindy, Chennai, Tamilnadu India.

Background: Acute Myeloid Leukemia (AML) is a very aggressive cancer with difficult treatment and poor outcomes. The treatment of these patients is quite challenging due to various reasons including the need for extensive supportive care, and high cost of therapy. Reports on outcomes from India are few. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12288-018-1023-0
Publisher Site
http://dx.doi.org/10.1007/s12288-018-1023-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439037PMC
April 2019
1 Read

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia.

Nat Biomed Eng 2019 Apr 15. Epub 2019 Apr 15.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Acute myelogenous leukaemia (AML) is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Here, we provide a comprehensive quantitative understanding of AML proteomic heterogeneities and hallmarks by using the AML Proteome Atlas, a proteomics database that we have newly derived from MetaGalaxy analyses, for the proteomic profiling of 205 patients with AML and 111 leukaemia cell lines. The analysis of the dataset revealed 154 functional patterns based on common molecular pathways, 11 constellations of correlated functional patterns and 13 signatures that stratify the outcomes of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41551-019-0387-2DOI Listing

Outcome of αβ T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission.

Bone Marrow Transplant 2019 Apr 15. Epub 2019 Apr 15.

Department of Hematopoietic Stem Cell Transplantation, Dmitriy Rogachev National Medical Research Сenter of Pediatric Hematology, Oncology and Immunology, Samory Mashela street, 1, Moscow, 117997, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0531-3DOI Listing

DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.

Cancer Biomark 2019 Apr 4. Epub 2019 Apr 4.

Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

Background: Aberrant epigenetic patterns are a hallmark of acute myeloid leukemia (AML). Mutations in profound epigenetic regulators DNMT3A and IDH1/2 often occur concurrently in AML.

Objectives: The aim was to analyze DNA methylation, hydroxymethylation and mRNA expression profiles in AML with mutations in DNMT3A and IDH1/2 (individually and in combinations). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-182176DOI Listing

[Cutaneous Manifestations of Sweet Disease].

Brain Nerve 2019 Apr;71(4):334-338

Division of Dermatology, Tohoku Medical and Pharmaceutical University.

Sweet disease, also known as acute febrile neutrophilic dermatosis, is a multisystem inflammatory disorder characterized by painful erythematous plaques and aseptic neutrophilic infiltration of various organs. It is also characterized by fever, polymorphonuclear leukocytosis, and painful erythematous cutaneous plaques. Cutaneous manifestations of Sweet disease are typically painful plaque-forming erythematous papules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416201271DOI Listing

Genetic Variants Associated with Cancer Therapy-Induced Cardiomyopathy.

Circulation 2019 Apr 16. Epub 2019 Apr 16.

Harvard Medical School, Boston, MA; MRC London Institute of Medical Sciences, Imperial College London, London, UK; Howard Hughes Medical Institute, Chevy Chase, MD; Brigham and Women's Hospital Boston MA.

Background: Cancer therapy-induced cardiomyopathy (CCM) is associated with cumulative drug exposures and pre-existing cardiovascular disorders. These parameters incompletely account for substantial inter-individual susceptibility to CCM. We hypothesized that rare variants in cardiomyopathy genes contribute to CCM. Read More

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.0
Publisher Site
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037934DOI Listing
April 2019
1 Read

Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.

Cells 2019 Apr 3;8(4). Epub 2019 Apr 3.

Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.

The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute myeloid leukemia (AML) is a common and lethal myeloid malignancy, the chemotherapy for AML has not changed in the last three decades. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8040312DOI Listing

3D Telomere Structure Analysis to DetectGenomic Instability and Cytogenetic Evolutionin Myelodysplastic Syndromes.

Cells 2019 Apr 2;8(4). Epub 2019 Apr 2.

Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, The Genomic Centre for Cancer Research and Diagnosis, R3E 0V9 Winnipeg, MB, Canada.

The disease course of myelodysplastic syndromes (MDS) features chromosome instability and clonal evolution, leading to the sequential acquisition of novel cytogenetic aberrations and the accumulation of these abnormalities in the bone marrow. Although clonal cytogenetic abnormalities can be detected by conventional cytogenetics in 50% of patients with MDS, such distinguishing patterns are lacking in the other 50%. Despite the increase in the prognostic value of some biomarkers, none of them is specific and able to discriminate between stable and unstable patients that subsequently progress to acute myeloid leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8040304DOI Listing

Leukemia Blast Crisis: A Simulation Case for Residents.

MedEdPORTAL 2016 Nov 18;12:10504. Epub 2016 Nov 18.

Emergency Medicine Resident, Perelman School of Medicine at the University of Pennsylvania.

Introduction: Oncologic emergencies are life-threatening and often require advanced team-management skills as well as a mastery of disease processes and therapeutic interventions. Simulation of an oncologic emergency case is a useful way to experience, reflect on, and practice these skills. This case involving a simulated patient in blast crisis was created as part of our Emergency Medicine (EM) Resident Simulation Curriculum at the Perelman School of Medicine at the University of Pennsylvania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15766/mep_2374-8265.10504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440397PMC
November 2016

The transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.

Exp Hematol 2019 Apr 12. Epub 2019 Apr 12.

Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address:

Reduced expression of the transcription factor PU.1 is frequently associated with development of acute myeloid leukemia (AML), whereas elevated levels of CITED2 (CBP/p300-interacting-transactivator-with-an-ED-rich-tail 2) enhance maintenance of both normal and leukemic hematopoietic stem and progenitor cells (HSPCs). Recent findings indicated that PU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2019.03.003DOI Listing

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries.

J Vis Exp 2019 Mar 31(145). Epub 2019 Mar 31.

Department of Pediatrics, Pennsylvania State University College of Medicine;

CCCTC-binding factor (CTCF)-mediated stable topologically associating domains (TADs) play a critical role in constraining interactions of DNA elements that are located in neighboring TADs. CTCF plays an important role in regulating the spatial and temporal expression of HOX genes that control embryonic development, body patterning, hematopoiesis, and leukemogenesis. However, it remains largely unknown whether and how HOX loci associated CTCF boundaries regulate chromatin organization and HOX gene expression. Read More

View Article

Download full-text PDF

Source
https://www.jove.com/video/59382/hox-loci-focused-crisprsgrn
Publisher Site
http://dx.doi.org/10.3791/59382DOI Listing
March 2019
1 Read

Affinity separation and subsequent terminal differentiation of acute myeloid leukemia cells using the human transferrin receptor (CD71) as a capture target.

Analyst 2019 Apr 15. Epub 2019 Apr 15.

Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX, USA.

The microfluidic detection of myeloblasts in blood via the human transferrin receptor (CD71) can serve as a diagnostic marker for acute myeloid leukemia (AML). Furthermore, CD71 expression is present in all proliferating cells and can capture target cells without prior knowledge of AML subtype. The use of anti-CD71 as the affinity ligand for AML detection in this work yields a capture efficiency and purity during peak CD71 expression of 92% and 62%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8an02357cDOI Listing

Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012.

JNCI Cancer Spectr 2019 Mar 9;3(1):pkz007. Epub 2019 Apr 9.

Background: Pediatric cancer incidence has been steadily increasing over the last several decades with the largest increases reported in infants. Few evaluations have looked at international pediatric cancer incidence trends in the youngest children. The aim of this analysis was to evaluate trends in cancer incidence in children under 5 years of age, overall and by type, using data from () from 1988 to 2012 (CI5 volumes VII-XI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pkz007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455426PMC

Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.

Front Oncol 2019 29;9:194. Epub 2019 Mar 29.

Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.

Epigenetic modifications, such as DNA methylation and histone modification, result in heritable changes in gene expression without changing the DNA sequence. Epigenetic regulatory enzymes such as DNA methyltransferases, histone methyltransferases, and histone deacetylases are involved in epigenetic modification. Studies have shown that the dysregulation caused by changes in the amino acid sequence of these enzymes is closely correlated with tumor onset and progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449417PMC

RAS responsive element binding protein 1 blocks the granulocytic differentiation of myeloid leukemia cells.

Oncol Res 2019 Apr 8. Epub 2019 Apr 8.

Central Laboratory of Yong Chuan Hospital, Chongqing Medical University, Chongqing, China.

RAS responsive element binding protein 1 (RREB1) is a transcription factor which implicated in RAS signaling and multiple tumors. However, the role of RREB1 in acute myeloid leukemia has not been studied. We found that RREB1 is overexpressed in AML patients and myeloid leukemia cell lines (NB4 and HL-60), and RREB1 expression was significantly decreased during granulocytic differentiation of myeloid leukemia cells induced by all-trans retinoic acid (ATRA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/096504018X15451301487729DOI Listing
April 2019
0.916 Impact Factor

MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide.

Oncol Res 2019 Apr 8. Epub 2019 Apr 8.

Department of Hematology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shanxi Province, People's Republic of China.

Although arsenic trioxide (ATO) is a well-known anti-leukemic drug used for acute promyelocytic leukemia treatment, the development of ATO resistance is still a big challenge. We previously reported that microRNA-204 (miR-204) was involved in the regulation of acute myeloid leukemia (AML) cell apoptosis, but its role in chemoresistance is poorly understood. In the present study, we showed that miR-204 was significantly increased in AML cells after ATO treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/096504019X15528367532612DOI Listing
April 2019
1 Read

Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.

Ann Hematol 2019 Apr 12. Epub 2019 Apr 12.

Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, 34 Zhongshan North Road, Quanzhou, 362000, Fujian Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03674-2DOI Listing

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.

Blood Cancer J 2019 Apr 12;9(4):46. Epub 2019 Apr 12.

EBMT Paris Study Office/CEREST-TC, Paris, France.

The role of umbilical cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active disease at allogeneic hematopoietic cell transplantation (allo-HCT) remains poorly investigated. In this study, we compared transplantation outcomes of 2963 patients with primary refractory or relapsed AML given CBT, 10/10 HLA-matched UD, or 9/10 HLA-matched UD allo-HCT from 2004 to 2015 at EBMT-affiliated centers. Neutrophil engraftment and complete remission rates in CBT, UD 10/10, and UD 9/10 recipients were 75 and 48%, 93 and 69%, and 93 and 70%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0204-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461673PMC

Gene Polymorphism of Tacrolimus-Metabolizing Enzymes Associated With Impaired Absorption of Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Transplant Proc 2019 Apr 26;51(3):998-1001. Epub 2019 Jan 26.

Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Objective: To elucidate the mechanisms by which orally administered tacrolimus was not absorbed in a patient following allogeneic hematopoietic stem cell transplantation.

Clinical Course: A 17-year-old girl with acute myeloid leukemia underwent HLA-haploidentical peripheral blood stem cell transplantation following fludarabine, busulfan, and total-body irradiation. Graft-vs-host disease prophylaxis was post-transplant cyclophosphamide, followed by intravenous tacrolimus and mycophenolate mofetil. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2019.01.061DOI Listing
April 2019
1 Read

Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK;

Somatic mutations in acute myeloid leukemia are acquired sequentially and hierarchically. First, pre-leukemic mutations, such as t(8;21) that encodes AML1-ETO, are acquired within the hematopoietic stem cell compartment, while signaling pathway mutations, including K-RAS activating mutations, are late events acquired during transformation of leukemic progenitor cells and rarely detectable in hematopoietic stem cells. This raises the possibility that signaling pathway mutations are detrimental to clonal expansion of pre-leukemic hematopoietic stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205351DOI Listing
April 2019
1 Read

Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Dept of Hematology, First Affiliated Hospital of Zhejiang Univ College of Medicine, Hangzhou, China;

Homoharringtonine, a plant alkaloid, has been reported to suppress protein synthesis and approved by U.S. Food and Drug Administration for chronic myeloid leukemia treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.208835DOI Listing
April 2019
1 Read

FLT3/ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA;

Acute myeloid leukemia is an aggressive hematologic neoplasm, and patients with an ITD mutation of the FLT3 receptor gene have a poor prognosis. FLT3/ITD interacts with DOCK2, a G effector protein that activates Rac1/2. Previously, we showed that knockdown of DOCK2 leads to decreased survival of FLT3/ITD leukemic cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.208843DOI Listing
April 2019
1 Read

A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia.

Cytogenet Genome Res 2019 Apr 12. Epub 2019 Apr 12.

Patients with childhood acute myeloid leukemia (AML) with complex karyotypes (CKs) have a dismal outcome. However, for patients with a KMT2A rearrangement (KMT2A-r), the prognosis appears to depend on the fusion partner gene rather than the karyotype structure. Thus, a precise characterization of KMT2A-r and the fusion partner genes, especially in CKs, is of interest for managing AML. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/499640
Publisher Site
http://dx.doi.org/10.1159/000499640DOI Listing
April 2019
3 Reads

Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model.

Neoplasia 2019 Apr 8;21(5):469-481. Epub 2019 Apr 8.

Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan; Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan. Electronic address:

Leukemogenic potential of MLL fusion with the coiled-coil domain-containing partner genes and the downstream target genes of this type of MLL fusion have not been clearly investigated. In this study, we demonstrated that the coiled-coil-four-helix bundle structure of EB1 that participated in the MLL/EB1 was required for immortalizing mouse bone marrow (BM) cells and producing myeloid, but not lymphoid, cell lines. Compared to MLL/AF10, MLL/EB1 had low leukemogenic ability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2019.03.006DOI Listing
April 2019
2 Reads

Frequency and Determinants of Invasive Fungal Infections in Children With Solid and Hematological Malignancies in a Nonallogeneic Stem Cell Transplantation Setting: A Narrative Review.

J Pediatr Hematol Oncol 2019 Apr 9. Epub 2019 Apr 9.

Princess Máxima Center for Pediatric Oncology.

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in children with cancer. An overview of studies on the frequency and determinants of IFI in pediatric oncology patients in nonallogeneic stem cell transplantation settings is lacking. We performed a literature review in Pubmed and Embase, and included 13 prospective and 23 retrospective studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001468DOI Listing
April 2019
3 Reads

Cytosine 5-hydroxymethylation regulated kit gene expression in acute myeloid leukemia.

J Biol Regul Homeost Agents 2019 Mar-Apr;33(2):345-353

Department of Respiratory Medicine, The First Hospital of Harbin, Harbin, China.

5-methyl cytosine (5mC) can be oxidized to 5-hydroxymethyl cytosine (5hmC) under the action of TET protein family, and 5hmC plays important roles in the pathogenesis of various tumors including acute myeloid leukemia (AML). In this study, we evaluated the role of 5mC and 5hmC levels in HL60 AML cells and bone marrow samples from AML patients for KIT gene expression to analyze 5hmC level in AML pathogenesis. Results showed that the expression and 5hmC level increased significantly of the KIT gene but the change of its 5mC level was not obvious after being treated by decitabine (DAC) in HL60 cells. Read More

View Article

Download full-text PDF

Source
April 2019
7 Reads